FDA Approves Lebrikizumab for Atopic Dermatitis
More than 1000 people age 12 years and older were enrolled in pivotal trials of the IL-13 inhibitor.
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-approves-lebrikizumab-atopic-dermatitis-2024a1000gpu?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-approves-lebrikizumab-atopic-dermatitis-2024a1000gpu?src=rss
Comments
Post a Comment